Floatz logo

Voxelotor

Idiopathic Pulmonary Fibrosis

Global Blood TherapeuticsSmall moleculePhase 2Dormant
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
31/ 100
Competitive Position
73/ 100

Competitive context

111 Active assets in the Idiopathic Pulmonary Fibrosis cohort.

Asset / SponsorPhaseRating
Pirfenidone
Endeavor Biomedicines, Inc.
Phase 4A
N-Acetyl-L-Cysteine
Endeavor Biomedicines, Inc.
Phase 4BBB
Nintedanib
Mannkind Corporation
Phase 4BBB
Nerandomilast
Boehringer Ingelheim
Phase 3BB
PREDNISONE TABLETS
Fondation Hôpital Saint-Joseph
Phase 3BB

View all 50 →

Same molecule, other indications

Voxelotor is also rated in:

sickle cell diseaseDormant
B
Indicative ·
57 / 100
View asset →
ulcer of lower limbsDormant
CCC
Indicative ·
48 / 100
View asset →
sickle cell diseaseDormant
CC
Indicative ·
41 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →